On January 26, 2010, Beike Biotech's stem cell preparation laboratory successfully passed ISO 9001 quality management system certification. Earlier, on January 23, the Jiangsu Stem Cell Bank, a Beike Biotech subsidiary, had already passed ISO 9001 quality management system certification and obtained the qualification certificate issued by the China Quality Certification Center (CQC), becoming a comprehensive stem cell bank in China to pass ISO 9001 quality management system certification. Since then, Beike Biotech has obtained a series of certifications in the standardized preparation and research of adult stem cells, stem cell storage, and technical support services. This further demonstrates the standardization of Beike Biotech's quality management and marks a brand-new height in its quality management.
As an attempt at a new model, Beike Biotech successively partnered in Jiangsu Province and with the China Medical City to establish the Beike Stem Cell Industrialization R&D Base, and set up branches such as Jiangsu Beike Biotechnology Co., Ltd. and the Jiangsu Stem Cell Bank. As the only stem cell bank in Jiangsu Province, the Jiangsu Stem Cell Bank is an important component of the Jiangsu Stem Cell and Biotherapy Public Technology Service Platform approved by the Jiangsu Provincial Department of Science and Technology, the Jiangsu Stem Cell and Regenerative Medicine Engineering Center approved by the Jiangsu Development and Reform Commission, and the Jiangsu Stem Cell and Regenerative Medicine Base approved by the Jiangsu Provincial Department of Health.
Hu Xiang, Chairman of Beike Biotech, said: "Through these public technology service platforms, we can integrate medical resources within Jiangsu Province, leverage the platforms' advantages, unify standards, perfect management, and achieve the goal of safeguarding the safety of clinical application research. So far, this new model has been developing well."
Since Beike Biotech's founding in 2005, in order to ensure the safety of stem cell technology in clinical application research, Beike Biotech has, with reference to relevant laws and regulations such as the Ministry of Health's "Regulations on Human Organ Transplantation," established a quality control system suited to the characteristics of stem cells and management norms for the industrialization process of stem cells. The company has actively referenced relevant AABB/FACT standards to continuously improve and upgrade its existing quality control system, innovatively undertaking standardized management of the stem cell industry.
"National policies and regulations are continually being improved. Beike Biotech has consistently followed these policies and regulations, and has continuously raised its requirements for self-regulation and self-improvement. We are innovating business models, strengthening channel building, and resolutely pursuing the mainstream direction of regenerative medicine, striving for more breakthroughs in tissue replacement, repair, and anti-aging, and advancing the industrialization of China's stem cells and the development of regenerative medicine." Hu Xiang, Chairman of Beike Biotech, is full of confidence in the future development of stem cell regenerative medicine.
